Senores Pharmaceuticals Limited
Price
₹372 - ₹391
Lot
38
Subs.
1.78
Expected Listing Earning

Exp. Premium(GMP):
195.50(50.00%)
IPO Details

Open Date: 20-Dec-2024
Close Date: 24-Dec-2024
Allotment Date: 26-Dec-2024
Listing Date: 30-Dec-2024
Listing Price: N/A
Face Value: ₹₹10 Per Equity Share Per Equity Share
Issue Price: ₹₹372-391 per equity share Per Equity Share
Issue Size: Approx 582.11 Crores
Market Lot (Min Amount): 38 Shares (₹14,858/-)
Valuations

Earning Per Share(EPS)N/A/-
P/E RatioN/A
RoNWN/A
Net Asset Value (NAV) - Post Issue:₹N/A/-
Company Financials (in Crore)

 Total AssetsTotal RevenueProfit After Tax
31 Mar,2024621.88217.3432.71
31 Mar,2023131.0539.028.43
31 Mar,202259.1514.630.99
Promoter(s)

Pre Issue Share HoldingN/A
Post Issue Share HoldingN/A
Company Promoter(s)
1. Swapnil Jatinbhai Shah
2. Ashokkumar Vijaysinh Barot
Issue Objective(s)

  1. Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(Havix), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility
  2. Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
  3. Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary
  4. Funding the working capital requirements of the Company;
  5. Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (SPI)and Ratnatris Pharmaceutical Private Limited (Ratnatris), to fund their working capital requirements.
  6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
About Company

The company's manufacturing unit is situated in Ahmedabad, Gujrat.

Competitive Strength

  1. The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility.
  2. A unique product portfolio tailored for regulated markets developed in a brief period.
  3. Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets.
Presence in the Emerging Markets with a product portfolio, including speciality or complex products.
  1. Robust R&D capabilities driving our differentiated portfolio of products.
  2. Experieced Management Team
Disclaimer

No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. 

Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.

If you are agree with app tems and condition to use the app. 

Thank you.